ADPT vs ITRI Comparison

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Itron Inc provides solutions that measure, manage, and analyze energy and water use. The company offers grid edge intelligence, energy and water management, smart city applications, Industrial Internet of Things (IIoT), and critical infrastructure and related services. It operates under the Itron brand and has four reportable segments: Device Solutions, Networked Solutions, Resiliency Solutions, and Outcomes. Key revenue is generated from the Networked Solutions segment, which includes a combination of communicating endpoints (e.g., smart meters, modules, endpoints, and sensors), network infrastructure, network design services, and associated headend management and application software designed and sold as a complete solution for acquiring and transporting robust application-specific data.